{"id":94691,"date":"2025-06-01T12:21:08","date_gmt":"2025-06-01T12:21:08","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/seers-proteograph-platform-enables-unprecedented-20000-sample-proteomics-study-with-korea-university-to-develop-ai-driven-diagnostics-for-cancers-in-young-adults\/"},"modified":"2025-06-01T12:21:08","modified_gmt":"2025-06-01T12:21:08","slug":"seers-proteograph-platform-enables-unprecedented-20000-sample-proteomics-study-with-korea-university-to-develop-ai-driven-diagnostics-for-cancers-in-young-adults","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/seers-proteograph-platform-enables-unprecedented-20000-sample-proteomics-study-with-korea-university-to-develop-ai-driven-diagnostics-for-cancers-in-young-adults\/","title":{"rendered":"Seer\u2019s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults"},"content":{"rendered":"
\n

First-of-its-kind study will use Seer\u2019s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics<\/em><\/p>\n

Seer\u2019s new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible\u00a0<\/em><\/p>\n

REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer\u2019s newly launched Proteograph\u00ae<\/sup> ONE Assay and SP200 Automation Instrument along with the Thermo Scientific\u2122 Orbitrap\u2122 Astral\u2122 mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes.<\/p>\n

Seer\u2019s latest platform advances will allow deep, unbiased proteomic analysis of\u00a020,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea\u2019s leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research.<\/p>\n

\u201cWe carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome\u2014including some attempting to replicate Seer\u2019s Proteograph platform\u2014and Seer\u2019s assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,\u201d said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. \u201cThe unique combination of Seer\u2019s latest platform and CPGR\u2019s proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.\u201d\u00a0<\/p>\n

By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized\u2014ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide.<\/p>\n

Transformational Technology for Population-Scale Proteomics<\/strong><\/p>\n

At the heart of the study is Seer\u2019s Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by:<\/p>\n